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The Modification of Diet in Renal Disease
4-calculated glomerular filtration rate is a better
prognostic factor of cardiovascular events than
classical cardiovascular risk factors in patients with
peripheral arterial disease
Jose-María Romero, MD,a,b Jordi Bover, MD, PhD,c Joan Fite, MD,a Sergi Bellmunt, MD,a,b
Jaime-Félix Dilmé, MD,a,b Mercedes Camacho, PhD,b Luis Vila, PhD,b and
Jose-Román Escudero, MD,a,b Barcelona, Spain
Objective:Risk prediction is important in medical management, especially to optimize patient management before surgical
intervention. No quantitative risk scores or predictors are available for patients with peripheral arterial disease (PAD).
Surgical risk and prognosis are usually based on anesthetic scores or clinical evaluation. We suggest that renal function is
a better predictor of risk than other cardiovascular parameters. This study used the four-variable Modification of Diet in
Renal Disease (MDRD-4)-calculated glomerular filtration rate (GFR) to compare classical cardiovascular risk factors with
prognosis and cardiovascular events of hospitalized PAD patients.
Methods:The study evaluated 204 patients who were admitted for vascular intervention and diagnosed with grade IIb, III,
or IV PAD or with carotid or renal stenosis. Those with carotid or renal stenosis were excluded, leaving 188 patients who
were randomized from 2004 to 2005 and monitored until 2010. We performed a life-table analysis with a 6-year
follow-up period and one final checkpoint. The following risk factors were evaluated: age, sex, ischemic heart disease,
ictus (as a manifestation of cerebrovascular disease related to systemic arterial disease), diabetes, arterial hypertension,
dyslipidemia, smoking, chronic obstructive pulmonary disease, type of vascular intervention, and urea and creatinine
plasma levels. The GFR was calculated using the MDRD-4 equation. Death, major cardiovascular events, and reinter-
vention for arterial disease were recorded during the follow-up.
Results: Patients (73% men) were a mean age of 71.38  11.43 (standard deviation) years. PAD grade IIb was diagnosed
in 41 (20%) and grade III-IV in 147 (72%). Forty-two minor amputations (20.6%), 21 major amputations (10.3%), and
102 revascularizations (50%) were performed. A major cardiovascular event occurred in 60 patients (29.4%), and 71
(34.8%) died. Multivariate logistic regression analysis showed that the MDRD-4 GFR, age, and male sex were
independent variables related to death and that the MDRD-4 GFR and chronic obstructive pulmonary disease were
related to major cardiovascular events. A statistically significant relationship was also found between serum creatinine
levels and reintervention rates.
Conclusions: The MDRD-4 GFR was a better predictor of risk of death or infarction than classical cardiovascular risk
factors in patients with PAD. This suggests that its routine use in the initial evaluation in patients with PAD is beneficial.
















fVascular disease in Spain represents 5.9% of consul-
tations in primary care, and 26.2% of these patients are
seen for ischemia of the lower limbs.1 According to the
TransAtlantic Inter-Society Consensus (TASC II) for the
management of peripheral arterial disease (PAD),2 the
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1324revalence of PAD ranges from 5% to 10%, reaching up
o 20% in patients aged 70 years. Of the total number of
AD patients, 10% to 35% are symptomatic with inter-
ittent claudication (IC), and critical limb ischemia
CLI) is present in 1% to 3%. The 5-year mortality rate of
atients with IC is 15%, and 75% is due to cardiovas-
ular events. The global annual rate of major cardiovas-
ular events, such as acute myocardial infarction (AMI),
erebrovascular event (CVE), and vascular death, is be-
ween 5% and 7%; however, the 1-year mortality rate for
LI may reach 25%.3
Ethnicity, sex, age, smoking, diabetes mellitus
DM), arterial hypertension, and dyslipidemia are con-
idered risk factors for PAD.3,4 Recent studies suggest
hat renal function, measured by the estimated glomer-
lar filtration rate (eGFR), is an independent prognostic
actor for cardiovascular disease.5-7 The relative contri-
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Volume 56, Number 5 Romero et al 1325nosis of these patients, such as hypertension or DM, is
debated.8-14
In Spain, 11% of the adult population has some degree
of chronic kidney disease.15 This has been related to an
increase in cardiovascular events and death, even in patients
with a moderate decrease in renal function.6,7,16,17
The Modification of Diet in Renal Disease (MDRD)
equation resulted from a retrospective analysis study ini-
tially aimed to evaluate the effect of a low-protein diet on
the progression of chronic kidney disease.18,19 An equa-
tion was used to improve the performance of the classical
Cockcroft-Gault (C-G) formula in calculating the eGFR. The
C-G formula was designed to estimate creatinine clearance
using age, weight, and plasma creatinine levels. By correct-
ing for body surface, theMDRD equation provides a better
estimate of the GFR than the creatinine clearance given by
the C-G formula. Thus, many medical societies recom-
mend using the MDRD equation for the early detection of
chronic kidney disease in populations.16,18,19
It is very important to have clinical risk scores and
parameters to evaluate surgical risk and to predict future
complications. This is necessary to optimizemedicalmanage-
ment because very few prognostic factors have been evaluated
and quantified in PAD patients. Our hypothesis is that renal
function calculated using theMDRD is a better risk predictor
and prognostic factor than the usual cardiovascular risk fac-
tors. The main objective of the present study was to compare
the traditional cardiovascular risk factors with the simplified
four-variable formula of the MDRD (MDRD-4) in survival,
appearance of ischemic events, and reintervention rates20 of
hospitalized patients with PAD.
METHODS
Patients. A life-table analysis was performed that in-
cluded patients admitted from 2004 to 2005 to the Depart-
ment of Vascular andEndovascular Surgery of theHospital de
la Santa Creu i Sant Pau in Barcelona, Spain. For inclusion in
our study, patients had to be aged18 years and admitted for
PAD grades IIb, III, or IV according to the Leriche-Fontaine
classification. The Leriche and Fontaine classification for
chronic lower limb ischemia, which is the most used classifi-
cation in Europe, consists of four grades:
● Grade I is defined as subclinical arteriopathy;
● Grade II is defined as IC, which in turn is subdivided as
grade IIa (claudication in 150 meters) and grade IIb
(claudication150 meters);
● Grade III is classically defined as ischemic rest pain;
and
● Grade IV is defined as any necrotic tissue ulcer or
lesion with an ischemia or gangrene.
The exclusion criteria were patients on hemodialysis,
renal transplant recipients, patients admitted with an acute
renal failure or within recovery phase, admission with tran-
sitory renal deterioration in patients with chronic renal
disease (CRD), individuals consuming special diets (such as
vegetarians), severe liver disease, body mass index 19
kg/m2 or 35 kg/m2, patients with severe muscle mass slterations, septic shock, and bilateral renal artery stenosis.
enal function in these cases is not a reliable parameter to
easure because baseline creatinine levels and eGFR are
athologic and unsettled. Also excluded were patients with
ymptomatic carotid or renal stenosis.
Patients were divided into two groups: (1) those with
AD grade IIb and (2) those with PAD grades III and
V.21 Patients were evaluated in a control visit from January
o March 2007, and those unable to visit were interviewed
y telephone. Patients or relatives were questioned about
ny new cardiovascular events such as AMI, CVE, need for
ascular reintervention, or death. Diagnoses were obtained
rom the clinical records or the medical reports provided by
atients or relatives. Because only one control visit was
erformed, there were not enough data to perform Kaplan-
eier curves.
Clinical diagnoses. The following criteria were used
o determine diagnoses:
● AMI—admission with clinical symptoms, electrocar-
diogram changes, or a positive enzymatic curve;
● CVE—history of transient ischemic attack or stroke,
or congestive heart failure, diagnosed by a cardiologist
and in treatment;
● Smoker—smoking in the previous 6 months;
● Previous vascular interventions—any type of arterial
vascular surgery or amputation;
● Diabetes mellitus—clinical history and use of insulin
or oral hypoglycemic medications (no distinction was
made between type 1 or 2);
● Arterial hypertension—clinical history and use of anti-
hypertensive drugs;
● Dyslipidemia—clinical history and use of hypolipi-
demia drugs;
● Chronic obstructive pulmonary disease (COPD)—
clinical history and medication;
● CRD—creatinine levels 120 mol/L or MDRD
values 60 mL/min/1.73 m2 based on the CRD
classification;
● PAD—grade IIb (claudication at150meters), grade
III (pain at rest), or grade IV (necrotic lesions); and
● GFR determination.
Urea and creatinine plasma levels were determined on
dmission. The levels were measured by Jaffe method with
Hitachi Modular D device (Roche Diagnostics, Mann-
eim, Germany). Urea levels were measured by the urease
ethod with a Hitachi Modular D device. The eGFR was
stimated by the simplified MDRD-4 equation: eGFR 
86  serum creatinine–1.154  age (years)–0.203  0.742
if female)  1.213 (if black).
Statistics. Statistical analysis was performed with SPSS
4.0 software (SPSS Inc, Chicago, Ill). A bivariate statisti-
al analysis was performed with contingency tables and the
2 test. Quantitative variables were described by an arith-
etic mean and its typical deviation. Likewise, multivariate
ogistic regression was used to determine the variables that
ere independently related. This provided the statistically
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operating characteristic (ROC) curves were constructed from
the models for MDRD and blood creatinine levels. Signifi-
cance was determined at 5% (  .05) and a value of P 
.05 was considered statistically significant. Continuous data
are reported as the mean 	 the standard deviation.
RESULTS
We recruited 188 patients, 149 men (73%) and 55
women (27%), who were aged 71.3 	 11.7 years. Indica-
tion for admission was PAD grade IIb in 41 (20.1%) and
grades III and IV in 147 (72.1%). During the follow-up, 21
patients (10.3%) were removed from our study because
they could not be contacted.
Patients underwent 102 revascularization interventions
(50%), 21 major amputations (10.3%), 42 minor amputa-
tions (20.6%), and 39 medical treatments without adjuvant
surgery (19.1%) during hospitalization. Events recorded
during follow-up included 71 deaths (34.8%), 46 nonfatal
coronary events (22.5%), 14 nonfatal CVEs (6.9%), and 54
new vascular interventions (26.5%).
The prevalence of the risk factors is reported in Table I.
Creatinine levels were 119.55 	 62.96 mol/L, and urea
levels were 9.459	 6.17 mmol/L (n 204). The MDRD
eGFR was 61.68 	 23.36 mL/min/1.73 m2 (n  204).
ROC curves were calculated for blood creatinine levels
and MDRD eGFR values related to an end point of death,
AMI, CVE, and need for reintervention. The ROC curve
for the MDRD eGFR showed an area of .704, a sensitivity
of 76.9%, and a specificity of 53% (P  .041) for a value of
60 mL/min/1.73 m2 “which is the limiting value for stage
I chronic kidney disease” (Fig 1, A). The ROC curve for
the creatinine blood level had an area of .623, a sensitivity
of 36.4%, and a specificity of 837% (P .043) for a value of
120 mol/L (Fig 1, B).
A multivariate logistic regression analysis showed the
following variables were independently related to death:
age (OR, 1.106; 95% CI, 1.057-1.158; P  .001), sex
(OR, 3.580; 95% CI, 1.507-8.502; P .004), andMDRD
eGFR (OR, 0.982; 85% CI, 0.964-0.999; P  .039). The
ROC curve for MDRD eGFR showed an area of .711, a
sensitivity of 67%, and specificity of 60.4% at a level of 60
Table I. Prevalence of risk factors
Diagnosis No. (%)
Coronary disease 56 (27.5)
Cerebrovascular 45 (22.1)
Congestive heart failure 23 (11.3)
Smoker 62 (30.4)
Former smoker 65 (31.9)
Previous interventions 75 (36.8)
DM 108 (52.9)
Arterial hypertension 119 (58.3)
Dyslipidemia 59 (28.9)
COPD 39 (19.1)
COPD, Chronic obstructive pulmonary disease; DM, diabetes mellitus.mL/min/1.73 m2 (Fig 2, A). The ROC curve for blood treatinine levels showed an area of .621, a sensitivity of
3.7%, and a specificity of 76.8% (P  .043) at 120
mol/L (Fig 3, A).
The probability of an AMI occurring was related to
OPD (OR, 3.144; 95% CI, 1.34-7.35; P  .008) and
DRD eGFR (OR, 0.965; 95% CI, 0.950-0.98; P 
001), obtaining an ROC curve with an area of .716, a
ensitivity of 63.5%, and a specificity of 69.6% for an
DRD eGFR of 60 mL/min/1.73 m2 (Fig 2, B). The
OC curve plotted for serum creatinine had an area of
709, a sensitivity of 60.9%, and a specificity of 79.8% (P 
049) at a level of 120 mol/L (Fig 3, B).
The probability of a CVE occurring was independently
elated to MDRD eGFR (OR, 0.976; 95% CI, 0.953-
.999; P .042), obtaining an ROC curve with an area of
688, a sensitivity of 57.4%, and a specificity of 71.4% for an
alue of 60 mL/min/1.73 m2 (Fig 2, C). The ROC curve
lotted for serum creatinine levels had an area of .663, a
ensitivity of 50%, and a specificity of 71.4% (P  .058) at
20 mol/L (Fig 3, C).
The only independent variable related to the probabil-
ty of requiring arterial surgery was blood creatinine level
OR, 1.005; 95% CI, 1.03-1.59; P  .048). The ROC
urve for MDRD eGFR showed an area of .577, a sensitiv-
ty of 58,5%, and a specificity of 52.9% for 60 mL/min/
.73 m2 (Fig 2, D). The ROC curve for serum creatinine
evels had an area of .591, a sensitivity of 38.9%, and a
pecificity of 72.3% at 120 mol/L (Fig 3, D).
Patients were stratified by contingency tables into four
roups according to the MDRD results: eGFR 15, 15 to
9, 30 to 59, and 60 mL/min/1.7 3m2. Table II sum-
arizes the results of the bivariate analysis of death, AMI,
VE, and the need for surgical reintervention with respect
o MDRD eGFR values according the stage of chronic
enal disease. Death was significantly increased with a de-
rease in MDRD eGFR (P  .001; Table II). The proba-
ility of having an AMI increased significantly with the
eduction in the MDRD eGFR (P  .001). CVE was not
tatistically significant by group stratification (P  .128).
he lowest levels of the MDRD eGFR reached statistical
ignificance (P .049) with the probability of new vascular
urgery.
ISCUSSION
The large increase in endovascular surgery has provided
ifferent therapies for treating patients. Thus, it is possible
ow to select the best treatment for each patient in terms of
raft patency over time. But whether the 5-year patency is
eally important is unknown, especially if patients have a
hort life expectancy. New methods need to be imple-
ented to allow the prediction death in vascular patients,
o choose the best technique according to the prognosis
nd baseline of the patient’s risk, and to optimize medical
anagement before surgery to improve outcomes.
Classical cardiovascular risk factors are related to the
isk of PAD.22,23 In practice, it is necessary to know
he prognosis and to determine the factors that influence
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Volume 56, Number 5 Romero et al 1327The cohort that we studied was dominated by men
(73%), a sex distribution similar to that found in other
studies.27,28 Men sustained an increase in death. As ex-
Fig 1. Receiver operating characteristic (ROC) curves f
of Diet in Renal Disease (MDRD) estimated glomerular
Fig 2. Receiver operating characteristic (ROC) curves fo
glomerular filtration rate values related to (A) global morta
events (CVEs), and (D) reintervention.pected, age was significant in global mortality (increase of b1% per year), with the mean age the same as reported by
ther authors.3,14,29 Smoking and DM were the most
mportant classical risk factors for the development of PAD
y composite end point (any event) for (A) Modification
tion rate values and (B) serum creatinine levels.
dification of Diet in Renal Disease (MDRD) estimated
) acute myocardial infarction (AMI), (C) cerebrovascularor anr Mo
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November 20121328 Romero et alfor reintervention.20 Our results agree with those reported
by Goessens et al.9 Other studies have reported that smok-
ing is not a risk factor for cardiovascular events in patients
with established PAD.14,29,30 The prevalence of DM was
slightly higher in our sample than in other studies,28,31
which may be because our diabetic population was aged.
According to Aboyans et al,32 DM is related more to
small-vessel disease than to large-vessel disease.4
The high prevalence of arterial hypertension (58.3%) in
Fig 3. Receiver operating characteristic (ROC) curves f
myocardial infarction (AMI), (C) cerebrovascular events
Table II. Summary of bivariate analysis of variables with r
stratified values
MDRD values Death AMI






AMI, Acute myocardial infarction; CVA, cerebrovascular accident.our patients agrees with the other data.22,23 Arterial hyper- sension is related to PAD, but our study found no relation-
hip with the evolution and follow-up complications of
atients with PAD.3,5,14,29
The low prevalence of dyslipidemia in our study is
nexpected. Undervaluation of dyslipidemia and the lack of
reatment are the most plausible explanations. Despite re-
orts by TASC II2 and other studies, we did not find a
ignificant relation between the severity of arterial disease
nd death. The increase in death among patients with
atinine levels related to (A) global mortality, (B) acute
Es), and (D) reintervention.
t to Modification of Diet in Renal Disease (MDRD)
CVA Reintervention rate Patients, No.
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Volume 56, Number 5 Romero et al 1329moderate renal involvement that does not require hemodi-
alysis has not been studied extensively. Several reports have
described a relation between new cardiovascular events and
a reduction in the GFR,5-12,15-17 although many studies
have not reported an association of PAD with cardiovascu-
lar events. The eGFR is the best index of renal function,
with values 60 mL/min/1.73 m2 associated with a sig-
nificant increase in cardiovascular complications.
Creatinine is the final product of creatine metabolism,
which freely circulates in the blood and is freely filtered by
the glomerulus and also in the proximal tubule in very small
amounts. Renal function has been evaluated classically by
plasma creatinine levels. Creatinine levels are affected by
different sources of biologic variability, multiple analytical
interferences, and important problems of standardization.
Serum creatinine levels vary, depending on age, sex, ethnic-
ity, muscle mass, and diet. Moreover, the relation between
the serum creatinine levels and theGFR is hyperbolic, causing
a low sensitivity in the detection of CRD. A reduction in the
GFR of at least 50% is required for creatinine levels to surpass
the reference intervals,33,34 which is particularly relevant in
elderly patients subjected to vascular surgery. Furthermore,
plasma creatinine levels are temporarily elevated in many
acute, transitory situations, becoming a nonrealizable param-
eter to quantify and stratify renal function.
Creatinine clearance, calculated from serum creatinine
levels and 24-hour urine excretion, is frequently used to
measure the GFR.However, this presents some limitations,
such as overestimation in individuals with normal renal
function, with differences in GFR estimation between 10%
and 20% compared with results obtained by inulin clearance
due to creatinine secretion in the proximal tubules. This
secretion varies in and among individuals and also increases
with a reduction in GFR, achieving values of 70% for an
eGFR 40 mL/min/1.73 m2.18 The current evidence
indicates that creatinine clearance overestimates the true
value of the GFR.33
The nephrologic evidence indicates that evaluation of
renal function should not be based only on serum creatinine
concentrations. Equations for the eGFR are more precise.34
These equations attempt to arrive at an eGFR from the serum
creatinine levels and some demographic and anthropometric
variables, among them age, sex, weight, height, and ethnicity,
thus avoiding the need for a 24-hour urine collection. The
MDRD equation was developed using a population of 1070
adults of both sexes with a predominance of Caucasians with
CRD using I-iothalamate clearance for the measurement of
the GFR.18,19,34 The equation is the result of a multiple
regression analysis, including six variables: serum urea,
creatinine and albumin concentrations, age, sex, and eth-
nicity, thus, known as MDRD-6. One year later, the same
group reported an abbreviated version with four variables,
which did not require urea or albumin concentrations.
Known as the MDRD-4, it has the same diagnostic efficacy
but is easier to apply. For any glomerular filtration value,
theMDRD equation is more precise than the C-G formula.
At present, the MDRD-4 is recommended by most scien-
tific societies.6,13 The limitations of using the MDRD Oquation have been considered as exclusion criteria in our
tudy.
In our study, from themultivariate analysis we obtained
igh values of the MDRD that protect against new cardio-
ascular events; however, the reductions of 1 point in the
DRD raised the risk of death by 2%. Nevertheless,
DRD levels are not related to the need for reintervention
n multivariate analysis but are on bivariate analysis.
Our results support the concept that PAD is a local
anifestation of a global systemic atherosclerosis.3 The
xact value of the GFR would provide objective data on
he level of the systemic effects in an individual. Our
esults are consistent with recently reported data that
howed the relevance of renal function to predict cardio-
ascular death.6,8-12,16,35,36
In this study, creatinine levels predicted the need for
ascular reintervention, whereas theMDRD values did not.
evertheless, we believe that an estimate of a patient’s
aseline renal function is not a reliable parameter because
ts value is influenced by many physiologic factors. The
esults of our multivariate analysis and ROC curves indicate
hat renal disease represented by MDRD values is a good
redictor of major cardiovascular complications (death,
MI, and CVE) in PAD patients with statistically signifi-
ant probability. Although creatinine levels can predict
hese events, ROC curves for MDRD levels are more
owerful predictors than creatinine values. It is important
o take into account that the MDRD eGFR is widely
onsidered a more reliable parameter to stratify renal im-
airment. That only serum creatinine levels were signifi-
antly related predictors to the need for vascular reinterven-
ion in our studymight be because of the limited number of
atients that we were able to study.
Another limitation of our study is that the diagnoses at
dmissionmay have biased the prevalence of some risk factors,
hich may have been undervalued and undertreated.
ONCLUSIONS
More work should be done with larger numbers of
atients and a prospective study designed with long-term
ollow-up to assess and complement the results. We pro-
ose that the MDRD eGFR value should be determined in
ll PAD patients on admission as part of their preoperative
valuation. The MDRD eGFR value provides an objective
easurement of the global health condition of PAD pa-
ients. It also gives an estimate of life expectancy and is a
imple and inexpensive test that helps to optimize the
hoice of vascular surgery.
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